R L Morton1, K Howard, J F Thompson. 1. Sydney Melanoma Unit, Discipline of Surgery, The University of Sydney, Sydney, NSW, Australia. rachaelm@health.usyd.edu.au
Abstract
BACKGROUND: The aim of this study was to determine the cost-effectiveness of wide excision (WEX) + sentinel node biopsy (SNB) compared with WEX only in patients with primary melanomas >/=1 mm in thickness. METHODS: A Markov model was populated with probabilities of disease progression and survival from the published literature. Costs were obtained from diagnostic-related group weightings and health outcomes were measured in quality-adjusted life years (QALYs). RESULTS: Base case analyses suggested that, over a 20-year timeframe, the mean total cost per patient receiving WEX only was AU $23,182 with 10.45 life years (LY) and 9.90 QALYs. The mean cost per patient for WEX + SNB was AU $24,045 with 10.77 LY and 10.34 QALYs. The incremental cost effectiveness ratio for WEX + SNB was AU $2,770 per LY and AU $1,983 per QALY. CONCLUSION: WEX + SNB appears to offer an improvement in health outcomes (in both LYs and QALYs) with only a slight increase in cost.
BACKGROUND: The aim of this study was to determine the cost-effectiveness of wide excision (WEX) + sentinel node biopsy (SNB) compared with WEX only in patients with primary melanomas >/=1 mm in thickness. METHODS: A Markov model was populated with probabilities of disease progression and survival from the published literature. Costs were obtained from diagnostic-related group weightings and health outcomes were measured in quality-adjusted life years (QALYs). RESULTS: Base case analyses suggested that, over a 20-year timeframe, the mean total cost per patient receiving WEX only was AU $23,182 with 10.45 life years (LY) and 9.90 QALYs. The mean cost per patient for WEX + SNB was AU $24,045 with 10.77 LY and 10.34 QALYs. The incremental cost effectiveness ratio for WEX + SNB was AU $2,770 per LY and AU $1,983 per QALY. CONCLUSION:WEX + SNB appears to offer an improvement in health outcomes (in both LYs and QALYs) with only a slight increase in cost.
Authors: Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode Journal: Trials Date: 2019-02-04 Impact factor: 2.279
Authors: Clara Curiel-Lewandrowski; Caroline C Kim; Susan M Swetter; Suephy C Chen; Allan C Halpern; John M Kirkwood; Sancy A Leachman; Ashfaq A Marghoob; Michael E Ming; James M Grichnik Journal: J Invest Dermatol Date: 2012-02-16 Impact factor: 8.551
Authors: Patrick L Quinn; Jin K Kim; Vishnu Prasath; Neal Panse; Thomas J Knackstedt; Ravi J Chokshi Journal: Arch Dermatol Res Date: 2022-03-18 Impact factor: 3.017
Authors: Hayley Standage; Alyssa R Hersh; Aaron Caughey; Matthew Taylor; John Vetto; Dale Han Journal: Ann Surg Oncol Date: 2020-09-19 Impact factor: 5.344
Authors: Alexander C J van Akkooi; Christiane A Voit; Cornelis Verhoef; Alexander M M Eggermont Journal: Ann Surg Oncol Date: 2010-02 Impact factor: 5.344
Authors: Frances Rapport; Andrea L Smith; Anne E Cust; Graham J Mann; Caroline G Watts; David E Gyorki; Michael Henderson; Angela M Hong; John W Kelly; Georgina V Long; Victoria J Mar; Rachael L Morton; Robyn Pm Saw; Richard A Scolyer; Andrew J Spillane; John F Thompson; Jeffrey Braithwaite Journal: BMJ Open Date: 2020-02-27 Impact factor: 2.692